BMY News & Events

Bristol Myers Squibb announced that the European Commission has granted approval to Sotyktu, or deucravacitinib, alone or in combination with methotrexate, for the treatment of active psoriatic arthritis, or PsA, in adults who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic therapy. Sotyktu, a once-daily oral, selective tyrosine kinase 2 inhibitor, is the first TYK2 inhibitor to be approved for the treatment of active PsA in the European Union. This EU approval is based on positive results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 clinical trials, which evaluated the efficacy and safety of Sotyktu 6 mg once daily in adults with active PsA. In both trials, treatment with Sotyktu resulted in significant improvement in disease activity, as measured by American College of Rheumatology 20 and Minimal Disease Activity. The overall safety profile of Sotyktu observed in individuals with active psoriatic arthritis was generally consistent with the safety profile in those with plaque psoriasis. The most common adverse reactions are upper respiratory infections, blood creatine phosphokinase increased, herpes simplex infections, oral ulcers, acneiform rash and folliculitis. Sotyktu is associated with the following special warnings and precautions for use: infections; pre-treatment evaluation for tuberculosis; malignancies; major adverse cardiovascular events, deep venous thrombosis and pulmonary embolism; immunizations; and excipients.

Bristol Myers' Massachusetts facility boosted drug production volume for clinical and commercial use by about 40% with AI, The New York Times' Farah Stockman reports. "We are able to now intervene in the batches during the manufacturing process and not have to wait until we get to the end," said Karin Shanahan, executive vice president, chief supply chain and operations officer for the company. These innovations have helped stabilize production of Orencia, a drug that treats autoimmune conditions such as rheumatoid arthritis using cells that are extremely difficult to grow, according to the report.

The major averages closed broadly higher as oil pulled back, though the ceasefire between the U.S. and Iran continues to be fragile. However, U.S. Defense Secretary Pete Hegseth said the ceasefire "certainly holds" and claimed that two U.S. commercial ships have already "safely transited the strait, showing the lane is clear."Meanwhile, earnings remain strong and AI capital expenditures continue to act as a structural tailwind. There is persistent capital flow into semis and hyperscalers, with expectations for massive multi-year spend cycles anchoring estimates higher.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Palantirprovided areport for Q1PayPalreportedand provided its outlook for Q2 and FY26Coinbaseannounced plans to, or 700 employeesPfizerreportedand reiterated its FY26 guidancePinterestreportedand provided Q2 revenue guidance2. WALL STREET CALLS:Ulta Beautyto Buy at BofA on improved earnings flywheelRobloxto Neutral at Piper Sandler on lack of visibilityArgusChipotleto Buy, expects comp growth to accelerateStephensRepay Holdings, sees "two binary outcomes"Tractor Supplyto Neutral at Piper Sandler3. AROUND THE WEB:FDA officials have blocked publication of several studies supporting the safety of widely used vaccines against Covid-19 and shingles in recent months, NY Times reportsHondaplans to shelve its $11B Canada EV plant as demand sputters, Nikkei reportsNissanis planning to cut roughly 10% of its European workforce and consolidate production lines at its Sunderland Plant as part of a broader restructuring effort, while exploring partnerships such as with Chery to utilize excess capacity and improve financial performance, FT saysBerkshirehas selected Gen Re chairman Charlie Shamieh to succeed Ajit Jain, Vice Chairman of Insurance Operations, when Jain decides to retire, Bloomberg reportsAppleis planning to release a new "Create a Pass' feature for its next iPhone software update, which will allow users to build and customize their digital tickets and gift cards in the Wallet app, Bloomberg says4. MOVERS:Backblazehigher afterand raising its guidance for FY26EverQuote, Digital Oceanand BRC Inc.increase afterDigi Power Xgains after signing aGeneDxlower afterand lowered its guidance for FY26BellRing Brandsand Adtranfalls after5. EARNINGS/GUIDANCE:Portillo's, with EPS and revenue missing consensusIPG Photonicsand provided guidance for Q2, with CEO Mark Gitin commenting, "I am pleased to share that first-quarter revenue came in above our expectations"Neuroneticsand backed its guidance for FY26Surgery Partnersand backed its guidance for FY26, with CEO Eric Evans commenting, "We are encouraged by our solid start to 2026"Expeditors, with EPS and revenue beating consensusINDEXES:The Dow rose 356.35, or 0.73%, to 49,298.25, the Nasdaq gained 258.33, or 1.03%, to 25,326.13, and the S&P 500 advanced 58.47, or 0.81%, to 7,259.22.

Officials at the Food and Drug Administration have blocked publication of several studies supporting the safety of widely used vaccines against Covid-19 and shingles in recent months, according to The New York Times' Christina Jewett, who reports this was confirmed by a spokesman for the Department of Health and Human Services. Publicly traded companies that make vaccines and drugs include Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX), AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY), and Sanofi (SNY).